Technical Analysis for DXB - Dimerix Ltd
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 3.08% | |
| 20 DMA Support | Bullish | 3.08% | |
| Down 3 Days in a Row | Weakness | 3.08% | |
| 1,2,3 Pullback Bullish | Bullish Swing Setup | 1.52% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 1.52% | |
| Doji - Bullish? | Reversal | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| NR7 | Range Contraction | -2.90% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 15 hours ago |
| Down 3% | about 15 hours ago |
| Down 2% | about 15 hours ago |
| Down 1% | about 15 hours ago |
| Up 1% | about 16 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
Dimerix Bioscience Ltd, formerly Dimerix Bioscience Pty Ltd, is engaged in developing and commercializing drug therapies and drug discovery tools. The Company’s business activity focuses on the clinical development of the Company’s therapeutic product (DMX200), which is targeted at treatind patients with chronic kidney disease; the development of other therapeutic oppurtunities generated from the use of its cell-based drug discovery assay technology (know as Receptor-HIT), and growing its assay business through the use of Receptor-HIT to assist third parties in their own drug discovery and development processes through contract research. DMX200 is a therapeutic approach to treating chronic kidney disease. It comprises two drugs: irbesartan and propagermanium.
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Disease Drugs Life Sciences Health Sciences Therapeutic Product Drug Discovery
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Health Disease Drugs Life Sciences Health Sciences Therapeutic Product Drug Discovery
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 0.37 |
| 52 Week Low | 0.052 |
| Average Volume | 5,041,235 |
| 200-Day Moving Average | 0.186 |
| 50-Day Moving Average | 0.306 |
| 20-Day Moving Average | 0.325 |
| 10-Day Moving Average | 0.340 |
| Average True Range | 0.020 |
| RSI (14) | 55.16 |
| ADX | 32.64 |
| +DI | 29.476 |
| -DI | 16.950 |
| Chandelier Exit (Long, 3 ATRs) | 0.309 |
| Chandelier Exit (Short, 3 ATRs) | 0.336 |
| Upper Bollinger Bands | 0.370 |
| Lower Bollinger Band | 0.281 |
| Percent B (%b) | 0.61 |
| BandWidth | 27.385 |
| MACD Line | 0.011 |
| MACD Signal Line | 0.013 |
| MACD Histogram | -0.0015 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.365 | ||||
| Resistance 3 (R3) | 0.365 | 0.355 | 0.360 | ||
| Resistance 2 (R2) | 0.355 | 0.347 | 0.355 | 0.358 | |
| Resistance 1 (R1) | 0.345 | 0.343 | 0.340 | 0.345 | 0.357 |
| Pivot Point | 0.335 | 0.335 | 0.333 | 0.335 | 0.335 |
| Support 1 (S1) | 0.325 | 0.327 | 0.320 | 0.325 | 0.313 |
| Support 2 (S2) | 0.315 | 0.323 | 0.315 | 0.312 | |
| Support 3 (S3) | 0.305 | 0.315 | 0.310 | ||
| Support 4 (S4) | 0.305 |
